Literature DB >> 15345288

Allogeneic bone marrow-derived flk-1+Sca-1- mesenchymal stem cells leads to stable mixed chimerism and donor-specific tolerance.

Weimin Deng1, Qin Han, Lianming Liao, Changhong Li, Wei Ge, Zhigang Zhao, Shengguo You, Hongye Deng, Robert C H Zhao.   

Abstract

OBJECTIVE: To investigate the possibility of flk-1+Sca-1- bone marrow-derived mesenchymal stem cells (bMSCs) to induce stable mixed chimerism and donor-specific graft tolerance.
METHODS: Allogeneic flk-1+Sca-1- bMSCs and syngeneic bone marrow (BM) cells were cotransplanted into lethally irradiated (8.5 Gy) recipient mice. FACS was used to analyze the chimerism 150 days later. Donor-type skin transplantation was performed to observe donor-specific immunotolerance in recipient mice. Mixed lymphocyte reaction (MLR) and mitogen proliferative assays were performed to evaluate proliferative response of splenocytes from recipient mice.
RESULTS: More than 5% donor-derived CD3+ cells were detected in splenocytes of recipient mice. Long-term survival of donor-type skin grafts was observed. MLR and mitogen proliferative assays showed that recipient mice had low immunoresponse to donor cells but retained normal ConA-induced proliferative response compared with normal mice.
CONCLUSION: Our results show for the first time that induction of stable mixed hematopoietic chimerism can be achieved with allogeneic flk-1+Sca-1- bMSC transplantation, which leads to permanent donor-specific immunotolerance in allogeneic host and results in long-term allogeneic skin graft acceptance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15345288     DOI: 10.1016/j.exphem.2004.06.009

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  20 in total

1.  Adipose-derived mesenchymal stromal cells from genetically modified pigs: immunogenicity and immune modulatory properties.

Authors:  Goutham Kumar; Hidetaka Hara; Cassandra Long; Humza Shaikh; David Ayares; David K C Cooper; Mohamed Ezzelarab
Journal:  Cytotherapy       Date:  2012-01-23       Impact factor: 5.414

2.  Mouse mandible contains distinctive mesenchymal stem cells.

Authors:  T Yamaza; G Ren; K Akiyama; C Chen; Y Shi; S Shi
Journal:  J Dent Res       Date:  2010-11-12       Impact factor: 6.116

3.  Twisting immune responses for allogeneic stem cell therapy.

Authors:  Shengwen Calvin Li; Jiang F Zhong
Journal:  World J Stem Cells       Date:  2009-12-31       Impact factor: 5.326

4.  In vivo Differentiation Potential of Mesenchymal Stem Cells: Prenatal and Postnatal Model Systems.

Authors:  Courtney Quinn; Alan W Flake
Journal:  Transfus Med Hemother       Date:  2008-05-16       Impact factor: 3.747

Review 5.  New advances in the mesenchymal stem cells therapy against skin flaps necrosis.

Authors:  Fu-Gui Zhang; Xiu-Fa Tang
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

6.  Hypoxic Preconditioning Augments the Therapeutic Efficacy of Bone Marrow Stromal Cells in a Rat Ischemic Stroke Model.

Authors:  Jin Chen; Yuanyuan Yang; Lihua Shen; Wensen Ding; Xiang Chen; Erbing Wu; Kefu Cai; Guohua Wang
Journal:  Cell Mol Neurobiol       Date:  2016-11-18       Impact factor: 5.046

7.  Flk-1+ mesenchymal stem cells aggravate collagen-induced arthritis by up-regulating interleukin-6.

Authors:  B Chen; J Hu; L Liao; Z Sun; Q Han; Z Song; R C Zhao
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

8.  The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro.

Authors:  Meng Wang; Yuan Yang; Dongming Yang; Fei Luo; Wenjie Liang; Shuquan Guo; Jianzhong Xu
Journal:  Immunology       Date:  2008-06-24       Impact factor: 7.397

Review 9.  Stem cell research in China.

Authors:  Lianming Liao; Lingsong Li; Robert Chunhua Zhao
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-06-29       Impact factor: 6.237

10.  Donor Recipient Chimeric Cells Induce Chimerism and Extend Survival of Vascularized Composite Allografts.

Authors:  Joanna Cwykiel; Arkadiusz Jundzill; Aleksandra Klimczak; Maria Madajka-Niemeyer; Maria Siemionow
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-05-10       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.